Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells.

被引：0
|
作者：
Hebib, Nadia C.
Larochelle, Fannie
Lutz, Bob
Lambert, John
Blattler, Walter
Roy, Denis Claude
机构：
[1] Hop Maisonneuve Rosemont Res Ctr, Montreal, PQ, Canada
[2] ImmunoGen Inc, Cambridge, MA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5558
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Role of Anti-CD33 for the Treatment of Acute Myeloid Leukemia - Systematic Review and Meta-Analysis
    Gurion, Ronit
    Gafter-Gvili, Anat
    Ram, Ron
    Vidal, Liat
    Raanani, Pia
    Shpilberg, Ofer
    BLOOD, 2012, 120 (21)
  • [22] Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia
    Lee, Chin-Cheng
    Lin, Che-Pin
    Lee, Yueh-Lun
    Wang, Giueng-Chueng
    Cheng, Yuan-Chih
    Liu, H. Eugene
    LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 897 - 905
  • [23] An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
    Hamann, PR
    Hinman, LM
    Beyer, CF
    Lindh, D
    Upeslacis, J
    Flowers, DA
    Bernstein, I
    BIOCONJUGATE CHEMISTRY, 2002, 13 (01) : 40 - 46
  • [24] Development of a 89Zr radiolabeled anti-CD33 antibody for PET imaging of Acute Myeloid Leukemia
    Buckway, Brandon
    Burrell, Lance
    Shami, Paul
    Kosak, Ken
    Lum, David
    Yap, Jeffrey
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [25] Bismuth-labeled anti-CD33 antibody for elimination of minimal residual disease in acute myeloid leukemia
    Mulford, D
    Chaitanya, D
    McDevitt, M
    Sgouros, G
    Finn, R
    Larson, S
    Apostolidis, C
    Morgenstern, A
    Scheinberg, D
    Jurcic, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 526 - 526
  • [26] Combining Anti-CD33 Chimeric Antigen-Receptor T Cells with the Hypomethylating Agent Decitabine to Treat Acute Myeloid Leukemia
    Ng, Kenneth K. H.
    Del Real, Marissa M.
    Wu, Jonas Jian
    Xue, Tongyuan
    Marcucci, Emanuela
    Yuan, Yate-Ching
    Marcucci, Guido
    Forman, Stephen J.
    Horne, David
    Budde, Lihua E.
    MOLECULAR THERAPY, 2023, 31 (04) : 145 - 146
  • [27] FUNCTIONAL EVALUATION OF ANTI-CD33 CAR-T CELLS GENERATED FROM HEALTHY DONOR AND ACUTE MYELOID LEUKEMIA PATIENTS
    Calvino, C.
    Ceballos, C.
    Inoges, S.
    Lopez-Diaz, de Cerio A.
    San Martin-Uriz, P.
    Calleja-Cervantes, M. E.
    Rodriguez-Marquez, P.
    Martin-Mallo, A.
    Rodriguez-Diaz, S.
    Martinez-Turrillas, R.
    Jauregui, P.
    Rifon, J.
    Rodriguez-Otero, P.
    Alfonso, A.
    Lasarte, J. J.
    Viguria, M. C.
    Redondo, M.
    Rodriguez-Madoz, J. R.
    Prosper, F.
    HAEMATOLOGICA, 2021, 106 (10) : 59 - 59
  • [28] Direct effect of bi-specific CD33 x CD64 antibodies on acute myeloid leukemia (AML) cells.
    Balaian, L
    Ball, ED
    BLOOD, 1999, 94 (10) : 593A - 593A
  • [29] Sequential cytarabine and α-particle immunotherapy with Bismuth-213-labeled anti-CD33 monoclonal antibody HuM195 in acute myeloid leukemia (AML).
    Burke, JM
    Jurcic, JG
    Divgi, CR
    McDevitt, MR
    Sgouros, G
    Finn, RD
    Larson, SM
    Scheinberg, DA
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [30] In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
    Minagawa, Kentaro
    Jamil, Muhammad O.
    Al-Obaidi, Mustafa
    Pereboeva, Larisa
    Salzman, Donna
    Erba, Harry P.
    Lamb, Lawrence S.
    Bhatia, Ravi
    Mineishi, Shin
    Di Stasi, Antonio
    PLOS ONE, 2016, 11 (12):
12345